143 related articles for article (PubMed ID: 9259409)
1. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
Camoratto AM; Jani JP; Angeles TS; Maroney AC; Sanders CY; Murakata C; Neff NT; Vaught JL; Isaacs JT; Dionne CA
Int J Cancer; 1997 Aug; 72(4):673-9. PubMed ID: 9259409
[TBL] [Abstract][Full Text] [Related]
2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
[TBL] [Abstract][Full Text] [Related]
4. Gö 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase.
Behrens MM; Strasser U; Choi DW
J Neurochem; 1999 Mar; 72(3):919-24. PubMed ID: 10037462
[TBL] [Abstract][Full Text] [Related]
5. K-252b potentiation of neurotrophin-3 is trkA specific in cells lacking p75NTR.
Maroney AC; Sanders C; Neff NT; Dionne CA
J Neurochem; 1997 Jan; 68(1):88-94. PubMed ID: 8978713
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
Albor A; Thraves PJ; Dritschilo A; Notario V
Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of trkA tyrosine kinase activity and inhibition by K-252a.
Angeles TS; Yang SX; Steffler C; Dionne CA
Arch Biochem Biophys; 1998 Jan; 349(2):267-74. PubMed ID: 9448714
[TBL] [Abstract][Full Text] [Related]
8. Suppression of p140trkA does not abolish nerve growth factor-mediated rescue of serum-free PC12 cells.
Taglialatela G; Hibbert CJ; Hutton LA; Werrbach-Perez K; Perez-Polo JR
J Neurochem; 1996 May; 66(5):1826-35. PubMed ID: 8780007
[TBL] [Abstract][Full Text] [Related]
9. Transphosphorylation of the neurotrophin Trk receptors.
Canossa M; Rovelli G; ShooterEM
J Biol Chem; 1996 Mar; 271(10):5812-8. PubMed ID: 8621450
[TBL] [Abstract][Full Text] [Related]
10. P53 associates with trk tyrosine kinase.
Montano X
Oncogene; 1997 Jul; 15(3):245-56. PubMed ID: 9233759
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphorylation of TrkB and TrkC and their signal transduction by alpha2-macroglobulin.
Hu YQ; Koo PH
J Neurochem; 1998 Jul; 71(1):213-20. PubMed ID: 9648868
[TBL] [Abstract][Full Text] [Related]
12. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors.
Tapley P; Lamballe F; Barbacid M
Oncogene; 1992 Feb; 7(2):371-81. PubMed ID: 1312698
[TBL] [Abstract][Full Text] [Related]
13. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Miknyoczki SJ; Dionne CA; Klein-Szanto AJ; Ruggeri BA
Ann N Y Acad Sci; 1999 Jun; 880():252-62. PubMed ID: 10415871
[TBL] [Abstract][Full Text] [Related]
14. Expression of TRK-T1 oncogene induces differentiation of PC12 cells.
Greco A; Orlandi R; Mariani C; Miranda C; Borrello MG; Cattaneo A; Pagliardini S; Pierotti MA
Cell Growth Differ; 1993 Jul; 4(7):539-46. PubMed ID: 8398895
[TBL] [Abstract][Full Text] [Related]
15. The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth.
Ashcroft M; Stephens RM; Hallberg B; Downward J; Kaplan DR
Oncogene; 1999 Aug; 18(32):4586-97. PubMed ID: 10467403
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the trk NGF receptor tyrosine kinase using recombinant fusion proteins.
Horvath CM; Wolven A; Machadeo D; Huber J; Boter L; Benedetti M; Hempstead B; Chao MV
J Cell Sci Suppl; 1993; 17():223-8. PubMed ID: 8144701
[TBL] [Abstract][Full Text] [Related]
17. Extended ceramide exposure activates the trkA receptor by increasing receptor homodimer formation.
MacPhee I; Barker PA
J Neurochem; 1999 Apr; 72(4):1423-30. PubMed ID: 10098845
[TBL] [Abstract][Full Text] [Related]
18. TrkA mediates the nerve growth factor-induced intracellular calcium accumulation.
De Bernardi MA; Rabins SJ; Colangelo AM; Brooker G; Mocchetti I
J Biol Chem; 1996 Mar; 271(11):6092-8. PubMed ID: 8626395
[TBL] [Abstract][Full Text] [Related]
19. Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase.
Hallberg B; Ashcroft M; Loeb DM; Kaplan DR; Downward J
Oncogene; 1998 Aug; 17(6):691-7. PubMed ID: 9715270
[TBL] [Abstract][Full Text] [Related]
20. Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells.
Baxter RM; Cohen P; Obermeier A; Ullrich A; Downes CP; Doza YN
Eur J Biochem; 1995 Nov; 234(1):84-91. PubMed ID: 8529673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
